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Kru¨ppel-like transcription factors (KLFs) have elicited signif-
icant attention because of their regulation of essential biochem-
ical pathways and, more recently, because of their fundamental
role in the mechanisms of human diseases. Neonatal diabetes
mellitus is a monogenic disorder with primary alterations in
insulin secretion. We here describe a key biochemical mecha-
nism that underlies neonatal diabetes mellitus insulin biosyn-
thesis impairment, namely a homozygous mutation within the
insulin gene (INS) promoter, c.-331C>G, which affects a novel
KLF-binding site. The combination of careful expression profil-
ing, electromobility shift assays, reporter experiments, and
chromatin immunoprecipitation demonstrates that, among 16
different KLF proteins tested, KLF11 is themost reliable activa-
tor of this site. Congruently, the c.-331C>G INSmutation fails
to bind KLF11, thus inhibiting activation by this transcription
factor. Klf11/ mice recapitulate the disruption in insulin pro-
duction and blood levels observed in patients. Thus, these data
demonstrate an important role for KLF11 in the regulation of INS
transcription via the novel c.-331 KLF site. Lastly, our screening
data raised the possibility that other members of the KLF family
may also regulate this promoter under distinct, yet unidentified,
cellular contexts. Collectively, this study underscores a key role for
KLF proteins in biochemical mechanisms of human diseases, in
particular, early infancy onset diabetesmellitus.
KLF7 proteins constitute a group of 16 different proteins that
are structurally characterized by the presence of an Sp1-like
three-zinc finger domain at their C terminus and a variable
transcriptional regulatory domain at their N terminus (1, 2).
This family of proteins has elicited significant attention because
of several important features. By regulating gene expression, at
the cellular level, these proteins canmodulate cell proliferation,
apoptosis, senescence, cell adhesion, angiogenesis, and metab-
olism (3, 4). Emerging evidence demonstrates that KLF genes
can regulate cardiovascular development, bone homeostasis,
brain function, pancreatic homeostasis, and liver morphogen-
esis and metabolic health (5). These data have led to a nascent
area in biochemistry, namely addressing to what extent KLF
proteins are involved in novel mechanisms of human diseases.
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Although their role in cancer pathways has been partially
characterized, the field is rapidly expanding to address their
mechanisms in altering human health. Most recently, a study
associating mutations in a KLF1-binding site with anemia has
been reported (6). These data have laid the foundation for
unique avenues of investigation into the biochemistry of KLF
proteins across the spectrum of human diseases.
Congruent with these new lines of discovery, the current
study primarily deals with the biochemical characterization of a
novel KLF-mediated transcriptional pathway that regulates the
insulin gene (INS). When disrupted, this pathway leads to neo-
natal diabetes mellitus (NDM), a monogenic and nonautoim-
mune form of diabetes in early infancy. The discovery is impor-
tant, because KLF-mediated pathways have been previously
associated with diabetes in human genetic studies. The first
study on the role of KLF proteins in diabetes revealed that mis-
sensemutations inKLF11 cause a formofMODY (7). Addition-
ally, it has been demonstrated that KLF11 may contribute to
MODY by directly regulating the promoter of PDX1 (8). Can-
didate gene studies have suggested that single-nucleotide poly-
morphisms in KLF11 and KLF7 loci may also associate with
type 2 diabetes risk (9, 10). Lastly, KLF14, a gene identified by
our laboratory, was recently found as a key link to this disease
via genome-wide association studies (11). However, mechanis-
tic information on how these pathways trigger disease is cur-
rently lacking. We report the characterization of a novel, func-
tional KLF cis-regulatory region located at the c.-331 position
within the human INS promoter that activates INS expression.
Mutations at this site have been recently described in NDM
patients (12), although its characterization as a KLF binding
site, its transcriptional activity, and the contribution of chro-
matin modifying enzymes to this function have not been
reported. Following genetic confirmation in an independent
NDM cohort study and the discovery of the c.-331 CG INS
promoter mutation, a family-wide screening of the 16 distinct
KLF proteins demonstrates that KLF11 is a consistent activator
of this promoter via a p300-mediated mechanism. ChIP assays
demonstrate that KLF11 binds to the conserved c.-331 KLF
binding site in the rat Ins2 gene, demonstrating that this site is
occupied by KLF11 in vivo. The c.-331 CG INS promoter
mutation present in NDM disrupts KLF11 binding to this
site, hindering INS transcription. In addition, the Klf11/
mouse recapitulates alterations in insulin biosynthesis. Col-
lectively, alterations in KLF11-mediated transcription by
three different mechanisms, namely KLF11 mutations
involved in MODY (7), as well as the two described here, the
c.-331 mutant INS promoter involved in NDM and Klf11
deletion in mice, strongly support a role for KLF11 protein in
insulin biosynthesis and diabetes development to a greater
extent than previously anticipated. Furthermore, our
screening data suggest that, in addition to KLF11, a small
subset of other KLF proteins could regulate this promoter
under distinct cellular contexts that remain to be defined.
More broadly, this study sheds light on a promising avenue
of biochemical research, namely how alterations of novel
KLF-mediated pathways may underlie the mechanisms of
important and common human diseases.
EXPERIMENTAL PROCEDURES
Molecular Genetic Analysis of the Human INS Promoter—
Mutations were screened in six NDM patients from consan-
guineous parents (clinical characteristics are shown in supple-
mental Table S1) who were referred to the French Network for
the Study of NDM (13). All of the patients were negative for any
missense mutations in KCNJ11, ABCC8, and INS or for abnor-
malities in the chromosome 6q24. Control individuals were 355
and 747 nondiabetic adults from France and Turkey, respec-
tively. Local ethics committees approved the study, and written
parental consent was obtained for genetic testing of subjects.
The human INS promoter (from nucleotide c.-448) was ampli-
fied by PCR (conditions available upon request to authors) and
sequenced using an automated 3730xl DNAAnalyzer (Applied
Biosystems). Electrophoregram reads were assembled and
compared with the reference sequence NM_000207.2, using
the SeqScape software (version v2.5; Applied Biosystems).
Nucleotide numbers and variant locations are displayed by
base numbers counting from the ATG translation initiation
codon according to the Human Genome Variation Society
nomenclature.
KLF Expression Analyses in Human Pancreatic Islets and 
Cells—For microarray analysis, human islets of Langerhans
(n  3) and sorted  cells (n  3) were isolated from adult
brain-dead donors in accordance with French regulations and
with local institutional ethical committee approval, as previ-
ously described (14, 15). RNAs from these samples were pro-
cessed using the TotalPrep RNA amplification kit (Ambion
Illumina). cDNAs were fluorescently labeled and hybridized to
the HumanHT-12_v4_BeadChip array according to the manu-
facturer’s instructions (Illumina). Fluorescence intensities were
controlled, quantified, and analyzed using BeadStudio (Illu-
mina). Each cDNA samplewas hybridized twice to themicroar-
ray. Expressionwas confirmed by standard PCR from two inde-
pendent cDNA samples of both human islets and  cells, using
the FastStart Taq (Roche Applied Science).
Cell Culture, Transfection, and Luciferase Assay—The INS
promoter reporter construct was a kind gift of DanielleMelloul
(Hadassah University Hospital, Jerusalem, Israel) (16). The
c.-331CG mutated INS promoter was generated using
QuikChange site-directedmutagenesis kit (Stratagene) accord-
ing to the manufacturer’s recommendations and verified by
sequencing. Rat INS-1 andmouse-TC-3 cells were cultured
as previously described (17, 18). The cell lines (80%confluent)
were electroporated in 0.4-cm cuvettes (2 106 cells) at 350 V
(INS-1) or 275 V (-TC-3) for one 10-ms pulse with 5g of the
wild-type (WT) or mutated human INS promoter reporter
plasmid using an ECM 830 square wave electroporator (BTX
Harvard Apparatus). Where indicated, the cells were co-trans-
fected with 5g of empty vector or each humanKLF construct.
In experiments with dominant negative (DN) p300, 3 g of the
WT INS promoter reporter plasmid was co-transfected with 3
g of parental control vector or KLF11 and 6 g of parental
control vector orDN-p300 (8). Forty-eight hours after transfec-
tion, the cells were lysed, and reporter activity was read using
the Luciferase assay system (Promega) and a 20/20 luminome-
ter (TurnerDesigns), according to themanufacturer’s protocol.
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The data in relative light units were normalized to control and
shown as themeans S.E. of themeans. The experiments were
performed in triplicate, three independent times. Statistics was
performed using Student’s t tests.
EMSA—Annealed oligonucleotides corresponding to the
c.-331 KLF binding site from the INS promoter (5-ATCTGC-
CGACCCCCCCACCCCAGGCCCTAATG-3), its human
c.-331CG mutation (5-ATCTGCCGACCCCCCGACCCC-
AGGCCCTAATG-3), and the corresponding rat Ins2
promoter (5-TGGCCATCTGCTGATCCACCCTTAATGG-
GACA-3) were end-labeledwith [-32P]ATP using T4 polynu-
cleotide kinase, as indicated by the manufacturer (Promega).
Recombinant fusion protein expression was induced in BL21
cells (Stratagene) and purified by using glutathione-Sepharose
4B affinity chromatography in accordance with the manufac-
turer’s instructions (Amersham Biosciences). Subsequently,
EMSAwas performed as previously described (19).Where indi-
cated, the followingwere added to the binding reactions: 2g of
anti-GST antibody, 2 g of anti-mIgG antibody, or 250-fold
molar excess unlabeled WT hINS probe.
ChIP Assay—ChIP assay was performed as previously de-
scribed (20). Briefly, INS-1 cells were transduced with adenovi-
rus containing polyhistidine-tagged KLF11 or an empty vector
control at amultiplicity of infection of 10 virus particles per cell.
A 143-bp region of the rIns2 promoter was amplified by PCR,
using specific primers to encompass the potential KLF binding
site (forward, 5-TAGCACCAGGCAAGTGTTTG-3; reverse,
5-GGGGTTACTGAATCCCCACT-3) and visualized by
2.5% agarose gel.
Generation of Klf11/ Mice—The Klf11 knock-out model
was generated at the University ofWashington, Seattle, follow-
ing standard homologous recombination techniques to inacti-
vate the endogenous Klf11 gene in embryonic stem cells, gen-
erating chimeras, and isolating colony founders carrying the
knock-out of this gene (21). This animal was originally gener-
ated in amixed background and subsequently transferred to the
Mayo Animal Facilities where it was crossed back into a pure
C57BL/6 background for more than 20 generations to produce
the inbred strain used in this study. In all of the experiments,
Klf11/ animals were compared with Klf11/ littermates.
Blood Glucose and Serum Insulin Measurements and Oral
Glucose Tolerance Test in Mice—Blood glucose measurements
were obtained from tail vein bleeding using OneTouch Ultra
glucometer (Lifescan; Johnson & Johnson). Serum harvested
from cardiac puncture was centrifuged at 500 g at 4 °C for 20
min and stored at20 °C for assays. Serum insulin levels were
measured with insulin ELISA kit usingmouse insulin standards
(Crystal Chem Inc.). For the oral glucose tolerance test
(OGTT), the mice were fasted overnight and were given D-glu-
cose solution at 2 g/kg of body weight by gavage. Serial blood
glucose and serum insulin measurements (0, 20, 60, and 120
min) were obtained from tail vein bleeding. Blood glucose and
serum insulin were measured as stated above and comparable
with previous studies (22, 23). Statistics were performed using
an analysis of variance model.
Immunohistochemistry—Insulin levels by immunohisto-
chemistry were examined in six Klf11/mice and their corre-
sponding gender-, age-, and weight-matched littermates. Anal-
ysis in each mouse was performed in islets from different
regions of the pancreas and utilizing 10 sections, sampling dif-
ferent depths within the organ. Sections were incubated with
anti-insulin antibody (Sigma) for 1 h at room temperature. The
detection reaction was performed as previously described (20).
RESULTS
Genetic Screening Identifies a Mutation within the INS Pro-
moter in NDM Patients That Impairs INS Transcription—We
searched for novelmechanisms underlying the regulation of the
human INS gene as revealed from genetic studies of the INS
promoter. We screened for genetic alterations that may target
the proximal INS promoter in patients with NDM (supplemen-
tal Table S1) from six consanguineous families who were neg-
ative for any missense mutations in KCNJ11, ABCC8, and INS,
or chromosome 6q24 abnormalities (i.e. the most frequent
causes of NDM (24–26)). Through this approach, we found
only one homozygous mutation (c.-331CG) within the INS
promoter in two NDM patients from consanguineous Turkish
families, which was not present in 1,002 control individuals
(two different control cohorts of 355 and 747 nondiabetic
adults from French and Turkish origins, respectively). The
c.-331CG mutation is located between the E1 and A1 ele-
ments (27–29), which is a highly conserved region across many
mammalian species (Fig. 1a). The existence of this mutation
was also confirmed in an independent cohort of NDM patients
(12), thus fulfilling theMedical Genetics gold standard of inde-
pendent validation, lending high reliability to the existence and
importance of thismutation.An extended genotype-phenotype
correlation of patients affected by this mutation as well as the
mechanism underlying its effect on insulin transcription
remained to be determined. Consequently, we provide a
detailed comparative description of the clinical genetic features
of NDM in patients carrying the c.-331 mutation and clinical
characteristics ofmembers fromone of the families (Fig. 1b and
supplemental Tables S1 and S2). Briefly, the two individuals
carrying the homozygous c.-331CG INS promoter mutation
displayed severe intrauterine growth retardation and alteration
in insulin biosynthesis that requires supplementation with this
hormone (0.3–0.4 units/kg/day) at birth. In the proband-1, dis-
continuation of insulin therapy triggered an abnormal OGTT,
showing a delayed peak of both plasma glucose and serum insu-
lin levels (supplemental Table S2). A recent study reported that
isolated rat  cells treated with glibenclamide exhibited higher
rates of proinsulin synthesis (30). Unfortunately, attempts to
increase insulin levels by administration of sulfonylurea did not
restore the metabolic balance because of a failure in normaliz-
ing the levels of this hormone. Ultimately, the proband-1
requires bolus insulin therapy (0.08 units/kg/day), further
reflecting its defect in insulin biosynthesis. Therefore, we
sought to investigate the functional behavior of the c.-331CG
mutated human INS promoter using reporter assays. Interest-
ingly, INS-1 cells demonstrate up to an 85% reduction ( 5.2%)
in promoter activity uponmutation, whereas-TC-3 cells have
reduced activity up to 96.4% ( 0.9%), thus recapitulating the
insulin defect observed in the mutated NDM patients (Fig. 1c).
These experiments also revealed that the severe disruption in
transcriptional activity caused by the c.-331CG mutation is
KLF Regulation of Insulin in Neonatal DiabetesMellitus
28416 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 32•AUGUST 12, 2011
 at UQ Library on M
arch 9, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
typical of alterations at the level of basal transcription, which, as
demonstrated by our laboratory in studies on KLF13-mediated
regulation of theCYP1A1promoter, also compromise activated
transcription (31). Collectively, the information provided here
on the c.-331CG mutation is of significant relevance to bio-
chemistry and medicine, because these results provide a more
complete genotype-phenotype correlation, which is critical to
the objectives of OnlineMendelian Inheritance inMan for fur-
ther research in this area. More importantly, it represents an
optimal model for functional studies aimed at describing novel
mechanisms that underlie forms of diabetes that result from
INS promoter dysfunction. Subsequently, a variety of methods
were used to identify how this mutation impairs insulin tran-
scription at the biochemical level.
The c.-331CGMutation Disrupts a Novel KLF-binding Site
That Activates INS Transcription in a p300-dependentManner—
The c.-331CG mutation maps to a CACCC sequence motif.
DNA binding data from SELEX and mutational analysis of
GC/GT boxes performed by our laboratory demonstrate that
the CACCC sequence conforms perfectly to a KLF binding site
(7, 8). Because the c.-331CG mutation strongly decreases
human INS promoter activity (Fig. 1c), we hypothesized that
FIGURE 1.Mutation and functional analysis of the INS promoter in NDM. a, diagram shows the human INS promoter sequence surrounding the c.-331 site
(c.-229 to c.-351). Thepreviously described cis-regulatory elements, E1 andA1, are in capital letters andunderlined. The TATAbox is also in capital letters, and the
transcription start site (TSS) is indicatedwith an arrow (c.-238). TheCACCCbox,which is recognizedby the KLFprotein family is in capital letters andhighlighted
in a gray boxwith the c.-331CGmutation of this element shown above the sequence. The numbering is described relative to the translational start site (c.1)
according to Human Genome Variation Society guidelines. b, pedigree of Family 1. Proband-1-CE is indicated by a black arrow. c, loss of INS promoter activity
with the c.-331CG mutation in both INS-1 and -TC-3 cells. Luciferase-based reporter assays were performed using the WT and c.-331CG mutant INS
promoters. The mean, standard error, and p values are shown for three replicates performed independently at least three times.
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this dysfunction is caused by impaired binding of a KLF activa-
tor protein, yet to be defined. KLF transcription factors form a
group of 16 proteins that bind with similar selectivity, although
unpredictable affinity, to the CACCC box (32). To identify
which KLF(s) bind and regulate the c.-331 CACCC site but not
themutatedGACCC site in NDMpatients, we designed a four-
tier biochemical screening approach.
First, we performed a careful genetic-based survey of which
KLF genes are expressed in human islets and  cells to identify
the first candidate regulators of the c.-331 CACCC site, as
NDM is due to severe defects of insulin secretion by the pan-
creatic  cell (24–26). For this purpose, we designed a KLF
family-wide expression microarray (Illumina technology). The
median levels of expression (MLEs) in three samples of islets
(MLEi) or FACS-assisted sorted  cells (MLE) were deter-
mined for each KLF gene. We found that among all KLF genes,
KLF1, KLF7, KLF8, KLF10, KLF12, KLF14, and KLF16 are not
expressed in both human islets and sorted  cells. In contrast,
KLF2, KLF4, KLF5, KLF6, KLF9, KLF11, and KLF13 are highly
expressed in both human islets and sorted  cells (250 MLE;
Fig. 2a). These datawere also confirmedbyRT-PCR (Fig. 2b). In
sorted human  cells, some expression/enrichment values
remained the same as in the whole islets, suggesting concentra-
tions of distinct KLF mRNA in this specific cell population,
whereas others decreased, suggesting that another cell type
within the islet may be enriched with those KLFs. This phe-
nomenon is better captured by the MLE/MLEi ratio. Fig. 2c
shows that distinct KLF genes were enriched by our FACS-
sorted human  cell population versus the islet, as indicated by
a MLE/MLEi ratio close to 1 ( 0.85) for KLF3 (0.99), KLF5
(0.86), KLF11 (0.95), and KLF13 (0.92), which demonstrates
that most of the expression signal detected in islets for these
genes was then recovered in the sorted  cells. On the other
hand, KLF2 (0.26), KLF4 (0.26), KLF6 (0.52), KLF9 (0.56), and
KLF15 (0.72) had aMLE/MLEi ratio of less than 0.85, indicat-
ing that the expression in the entire islet cannot be accounted
for by its expression in sorted  cells. However, it is important
to note that in the case of KLF3 and KLF15, the relative abun-
dance of transcript was not significant in either islets (MLEi) or
sorted  cells (MLE) (KLF3: MLEi  48.9, MLE  48.5;
KLF15: MLEi 20.2, MLE 14.5). All of these values, as well
as their relative enrichment in either islet or  cells, as defined
by the percentage of genes that fall lower in expression levels
than each KLF protein, are provided in supplemental Table S3.
This careful array experiment demonstrates that pancreatic
islet  cells are significantly enriched in specific KLF proteins
FIGURE2.ExpressionprofilingofKLFgenes reveals enrichmentofdistinctKLFproteins inhuman islets and cells. Illumina-basedKLFgene family-wide
array profilingwas used to determine the expression profile in whole human islets and FACS-assisted sorted human cells. a, heatmap indicating the relative
value of expression of each KLF gene in a particular sample (see supplemental Table S3 for numerical data). Color scale of values is shown below. b, expression
of KLFproteins found tobe expressedby Illumina arraywas confirmedbyRT-PCR in two cDNA samples of each, sortedhuman cells andhuman islets. Positive
control () is total human cDNA.MW, molecularweightmarker. c, histogram showing the relative enrichment of KLF genes specifically in human cells within
the islet as defined by the ratio between themedian level of expression in sorted cells comparedwithwhole islets (MLE/MLEi). KLF3, KLF5, KLF11, and KLF13
had values close to 1 (0.85), indicating thatmost of the expression signal detected in islets for these geneswas recovered in the sorted cells. Note, however,
that the abundance of KLF3 transcript was not significant in either whole islets or  cells, as shown in Fig. 2A.
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that likely influence the biology of these cells by driving a com-
plex cascade of gene expression. In addition, this constitutes the
most comprehensive expression analysis ofKLF genes in cells
thus far reported and, as the first step of our screening, was
efficient in ruling out nine KLF proteins (KLF1, KLF3, KLF7,
KLF8, KLF10, KLF12, KLF14, KLF15, andKLF16) as candidates
for the regulation of the c.-331 CACCC site and warranted fur-
ther testing of the remainingKLF familymembers viawell char-
acterized biochemical assays.
Next, we performed reporter experiments to assess which
KLF proteins activate the wild-type but not the mutant INS
promoter. Because the investigation of human INS gene regu-
lation is problematic, because human  cell lines are unavail-
able, we performed this reporter-based screening step using
two independently derived rodent lines, rat INS-1 (Fig. 3a) and
mouse -TC-3 (Fig. 3b)  cells. For the proper evaluation of
these experiments, we statistically defined the a priori criteria
that proteins that could only regulate the transfected human
INS promoter in two different, well established  cell models
constitute the best candidates for transcriptional regulators of
the c.-331 CACCC site and thus justify additional biochemical
characterizations. Fig. 3a demonstrates that the KLF family
members, KLF10 (4.5-fold  0.17), KLF11 (3.3-fold  0.11),
KLF13 (4.2-fold  0.25), KLF14 (3.8-fold  0.22), and KLF16
(3.2-fold  0.31) significantly increased wild-type INS pro-
moter activity in INS-1 cells, but this activity was abolished by
the c.-331CGmutation.However, according to our array data
(Fig. 2), KLF10, KLF14, and KLF16 are not readily expressed in
 cells. Fig. 3b shows that in -TC-3 cells, KLF11 activated this
promoter 2.3-fold ( 0.08), whereas KLF5 and KLF6 had less
effect (mean 1.6- and 1.8-fold, respectively). Because KLF5 and
KLF6 had no activity in INS-1 cells, following our rigorous a
priori evaluation criteria, they were eliminated as candidates.
Notably, however, KLF11 consistently activated the INS pro-
moter in both cell lines and is highly present in both human
islets and  cells. Thus, KLF11 became our focus as a regulator
of the c.-331 CACCC site. Mechanistically, Fig. 3c demon-
strates that KLF11 requires the functional histone acetyltrans-
ferase, p300, to activate the human INSpromoter in the INS-1
cell line, thus linking regulation of the c.-331 mutation to a
distinct chromatin-mediated pathway. KLF11 increased activ-
ity of the wild-type INS promoter, but co-transfection with
DN-p300 abolished this activity (74% of empty vector control
with DN-p300  6.7%), supporting a significant role for this
histone acetyltransferase in normal  cell function and insulin
secretion. Other histone acetyltransferases such as p300/CREB
binding protein-associated factor and CREB binding protein
did not modify the activating function of KLF11 (data not
shown). This result is important, because p300 mechanisms
and acetylation of histones have been shown by ChIP to be
dominant in INS expression (33–35).
In our third screening step, we assessed whether the
c.-331CGmutation impairs KLF11-mediated INS activation.
By EMSA, we investigated whether KLF11 binds the c.-331
CACCC site in both human INS and rat Ins2 promoters. More
importantly, we determined whether the human c.-331CG
mutation disrupts this binding. We analyzed the ability of
KLF11 to bind to the c.-331 wild-type site with a 32-mer probe
containing the CACCC box. The extended length of the EMSA
probe was able to better represent the context within the
human INS promoter than shorter sequences (corresponding
to c.-346 to c.-315 nucleotides; Fig. 4a). We also assessed the
ability of KLF11 to bind to a similar probe representing the
NDM c.-331CGmutation, which alters the coreCACCC box
toGACCC. Fig. 4a demonstrates that KLF11 binds to the wild-
type INS promoter binding site (lane 4). This binding, however,
was significantly disrupted using the c.-331CGNDMmutant
sequence (lane 6). The binding activity of KLF11 to this
sequence was found to be specific by supershift using antibod-
ies (lanes 7 and 8). Competition assays demonstrated that the
KLF11 binding activity was competed with unlabeled wild-type
probe (lane 9). A probe corresponding to the same conserved
region of the rat Ins2 promoter also demonstrated that KLF11
indeed forms a complex with this site in vitro (lanes a–c).
Together, these studies demonstrate that KLF11 specifically
binds to the c.-331 CACCC site of the human INS and rat Ins2
promoters. Thus, these data characterize a novel biochemical
role for KLF11, namely to bind and regulate the WT c.-331
CACCC site of the INS promoter and reveal that this binding is
disrupted by the c.-331CGmutation found in NDM.
Finally, we performed ChIP assays to determine whether the
region of the evolutionarily conserved CACCC site was occu-
pied in vivo by KLF11. The conservation of this site in the rat
Ins2 promoter allowed the utilization of ChIP assays in INS-1
cells to assess whether KLF11 binds to the endogenous pro-
moter in vivo. Fig. 4b shows that indeed this KLF site within the
Ins2 promoter is an actual target of KLF11. It is noteworthy that
in this study, we utilized epitope-tagged KLF11 protein be-
cause, despite extensive testing and experimentation, a specific
KLF11 antibody that is useful for ChIP assays remains to be
developed (36). In conclusion, our results demonstrate that dis-
ruption in KLF11-mediated activation of the c.-331 CACCC
site within the human INS promoter compromises a p300-de-
pendent chromatin remodeling pathway that regulates basal
INS transcriptional activity, which may also impact its induci-
ble expression and contribute to the pathogenesis of NDM.
Lastly, our results do not rule out the possibility that other KLF
proteins, distinct fromKLF11,maymediate this function under
different cell biological contexts (e.g. activation of different sig-
naling pathways).
Mouse Modeling Experiments Demonstrate That Disruption
of Klf11 Function Impairs Insulin Biosynthesis—The participa-
tion of KLF11 in the regulation of insulin biosynthesis in vivo
was further supported bymouse genetic experiments utilizing a
Klf11/mouse in a genetically pureC57BL/6 background, as a
functional model to study globally disrupted KLF11-mediated
transcription. Interestingly, knock-out of Klf11 in mice results
in decreased insulin levels in serum from nonfasting (2.16 
0.40 versus 0.68  0.10 ng/ml, p 	 0.05, n  8) and fasting
(1.01 0.20 versus 0.29 0.05 ng/ml, p	 0.05, n 8) animals
(Fig. 5, a and b, respectively). Based upon our biochemical anal-
ysis of transcriptional control of the c.-331 KLF site through
KLF11 binding, we hypothesized that reduced insulin levels in
Klf11/ mice may be due to a failure to fully activate the
murine Ins2 promoter that contains the conserved KLF box.
Congruent with the blood biochemistry data, a reduction in
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insulin production was initially evidenced by semi-quantitative
immunohistochemistry, which showed concomitant attenua-
tion of the insulin signal in Klf11/ islet  cells (Fig. 5c). For a
more quantitative assessment, we measured the expression of
the Ins2mRNA levels in Klf11/mice using, for internal data
consistency, the same microarray technique employed to mea-
sure the expression of KLF genes in human islet. Indeed, the
levels of insulin in theKlf11/ pancreas were 66% ofKlf11/
FIGURE 3. KLF11 activates the human INS promoter but not the c.-331C>Gmutant promoter. a, rat INS-1  cells were co-transfected with either the WT
or c.-331CGmutant INS promoter reporter construct and each of the KLF family members (KLF1–KLF16) or empty vector (EV) control. Luciferase activity was
measured, and the means and standard errors (as indicated by the error bars) were determined for each experimental condition from triplicates of three
independent experiments. The dashed line represents the 2-fold cut-off value for significant activation above empty vector control. b, KLF11 was the only KLF
familymember to increaseWT INSpromoter activitymore than 2-fold in-TC-3 cells, but this activitywas abolishedwith the c.-331CGmutant promoter. His-
and FLAG-tagged KLF protein expression was confirmed by Western blot (lower panel). c, KLF11 requires functional p300 to activate the INS promoter. INS-1
cells were co-transfected with the WT INS promoter and either empty vector control or KLF11 along with an empty vector control or a DN-p300. Note that
plasmidDNAamountswere adjusted to accommodate either control vector orDN-p300; thus KLF11 activationof theWT INSpromoterwas adjusted to 1.6-fold
above empty vector control. The mean promoter activity standard error is shown relative to WT INS promoter transfected with control empty vector.
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littermates values (p 0.002). This result was also validated by
RT-PCR (Fig. 5d). In agreement with decreased insulin, these
mice showed abnormal responses toOGTT. Peak glucose levels
occurred at 20 min in both Klf11/ and control groups; how-
ever, Klf11/mice had 40% lower values than Klf11/ litter-
mates (371.2  41.6 versus 265.9  19.8, p 	 0.05; Fig. 5e, left
panel). At 60 and 120 min, blood glucose levels in Klf11/
mice remained lower than inKlf11/ littermates (178.6 14.8
versus 220.9 17.7 at 60 min and 141.8 11.7 versus 182 16
mg/dl; p 	 0.05). In addition, serial plasma insulin levels were
checked at each time point of the OGTT. There was a 2-fold
increase in insulin levels compared with baseline at the 20-min
time point (0.24 0.02 to 0.48 0.17 ng/ml) in Klf11/mice
versus only a 0.3-fold increase in Klf11/ littermates (0.47 
0.05 to 0.64  0.35 ng/ml p 	 0.05; Fig. 5e, right panel). This
rapid increase in insulin in Klf11/mice did not persist either
at 60 or 120 min. As in many other studies that tried to model
diabetes-associated alterations in mice, including Hnf1a, Gck,
and Glut2 (37–40), Klf11/ animals did not ultimately
develop diabetes, likely because of concomitant alterations of
metabolic pathways in peripheral tissues (41, 42). This notion is
supported by our gene expression profiling of thesemice, which
demonstrates that Klf11/mice display abnormal expression
of severalmetabolic enzymes in adipose andmuscle tissue (sup-
plemental Fig. S1), where KLF11 plays a key physiological role
(43). This type of effect is likely due to the fact that the disrup-
tion of Klf11-mediated transcription is global inKlf11/mice,
rather than localized as with the c.-331CG INS mutation.
Nevertheless, the disruption of insulin homeostasis is the first
key phenotypic abnormality ever described for the Klf11/
mice. Togetherwith the rest of our comprehensive biochemical
experiments, these mouse genetic experiments support a key
role for the KLF11/p300-mediated pathway in the regulation of
INS transcription.
DISCUSSION
Recent reports indicate that KLF proteins are involved in
mediating several biochemical mechanisms that lead to human
diseaseswhendisrupted (5). Thus, the search forKLF-mediated
mechanisms is fueling a new and promising area of research in
both biological chemistry and medicine. The current study
deals with the characterization of a mutation in a novel KLF
binding site that regulates insulin biosynthesis, leading to
NDM.Thepatients affected by thismutation experience typical
time-dependent fluctuations in their insulin and glucose levels,
suggesting that under certain circumstances, the lack of insulin
biosynthesis may be compensated, most likely at the level of
peripheral resistance. Unfortunately, however, this mutation
ultimately leads to severe disease with intrauterine growth
retardation and postnatal morbidity. Therefore, identifying the
mechanisms underlying the regulation of both the wild-type
and mutated INS promoters is of paramount importance to
uncover the role of KLFs in pancreatic  cell biochemistry.
These data will significantly expand the repertoire of mecha-
nisms underlying the development of diabetes.
Our investigations were encouraged by the observation that
the c.-331CG mutation has been identified in two indepen-
dent cohorts of human subjects. The high reliability that repe-
tition of genetic data provides led us to design a KLF family-
wide screening for identifying potential KLF protein(s) that can
bind this site and activate the wild-type INS promoter but not
the mutant counterpart. In an unbiased approach used previ-
ously in our laboratory (44, 45), we screened all of the 16 differ-
ent KLF proteins for their ability to perform this function.
These experiments revealed that KLF11 is the most consistent
activator of the locus. Although our study focused on KLF11
because of our experimental exclusion criteria of other candi-
dates, it does not eliminate other KLF proteins in different bio-
logical contexts.
These data should be discussed in lieu of previous biochem-
ical and diabetes genetic studies, which confirmed that some of
the KLF proteins, reported here as potential regulators of the
INS promoter, are indeed diabetes susceptibility genes (7–11).
Therefore, previous reports, the data of the current studies, and
investigations using high resolution genetic and biochemical
FIGURE 4. KLF11 binds to the c.-331 novel KLF binding site, which is dis-
rupted by the c.-331C>G NDM mutation. a, EMSA was performed using
either the wild-type human INS CACCC promoter site (WT hINS; lanes 1, 3, 4,
and 7–9) or the c.-331CG mutation (mut hINS; lanes 2, 5, and 6) with GST
protein (lanes 3 and 5), recombinant KLF11 (KLF11; lanes 4 and 6–9), or probe
alone (lanes 1 and 2). The specific complexes that form between KLF11 and
the probe are indicated on the left. Although the anti-GST antibody shifted
the KLF11-WT hINS complex (lane 7), the same amount of an anti-mIgG anti-
bodydidnot (lane 8). Notably, KLF11didnot shift the c.-331CGmutant hINS
probe (lane 6). Furthermore, the addition of an excess of unlabeled WT hINS
probe competed for the binding (lane 9). Finally, the corresponding region of
the rat Ins2 promoter was utilized as a probe for gel shift assays (WT rIns2,
lanes a–c) with control GST protein alone (lane b), KLF11 (KLF11; lane c), or
probealone (lanea),whichdemonstrated that KLF11 indeed formsa complex
with this region of the rat Ins2 promoter in vitro (lane c). b, KLF11 occupies the
CACCC box of the rat Ins2 promoter in vivo. The region of the Ins2 promoter
fragment containing the conserved CACCC box was amplified by PCR after
ChIP from KLF11-infected cells but not the empty vector-infected sample
immunoprecipitated (IP) with the same anti-His antibody (negative control),
demonstrating that this region of the rIns2 promoter is a target of KLF11 in
INS-1 cells. Positive amplificationof PCRproducts is shown in the inputDNA
lanes, demonstrating that this region of the rIns2 promoter is present in all
samples before immunoprecipitation. Anti-mouse IgG was used as an addi-
tional negative control (data not shown).MW, molecular weight marker.
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techniques underscore the emerging importance of KLF pro-
teins in the etiopathogenesis of nonautoimmune diabetes.
Asmentioned, impairment inKLF11-mediatedmechanisms,
because of KLF11mutations (7) or mutation in the c.-331 KLF
site of INS promoter as described here, leads to impairment in
INS transcription in MODY and NDM. Using genetically engi-
neered mice, we sought to partially model the impairment in
KLF11-mediated processes by deleting this gene through
homologous recombination. Notably, this animal recapitulates
the defect in insulin biosynthesis observed in human situations
that are characterized by alterations in the biochemical func-
tion of KLF11. This result is highly informative because the
mechanism of Klf11 disruption used in this mouse model
causes alterations in insulin biochemistry similar to what is
observed in humans although via different mechanisms,
namely the functional disruption of this protein as observed
in MODY versus the lack of its transactivating DNA binding
function on the INS promoter in NDM, respectively. There-
fore, the existence of three different mechanisms of disrup-
tion of KLF11-mediated transcriptional regulation that
result in impaired insulin biosynthesis in both human and
mice underscores the importance of this transcription factor
in this key biochemical process.
Complementary observations reported here indicate that, in
addition to KLF11, a reduced subset of KLF proteins may be
able to also regulate insulin biosynthesis. For instance, these
other KLF proteins may regulate promoters under basal or sig-
naling-induced regulated conditions. Thus, it is currently diffi-
cult to predict under what biological context these other KLF
factors could regulate INS expression. In this regard, character-
izing the role of these other KLF genes in diabetes and the
cellular contexts in which these phenomena occur will
require significant efforts that are beyond the scope of this
article. Nevertheless, the discovery of additional KLF pro-
teins as candidates for regulation of insulin biosynthesis
offers significant value added by providing the background
FIGURE 5. Klf11/mice display defects in insulin biosynthesis and blood levels. a, nonfasting insulin levels in Klf11/ animals were significantly lower
when compared with Klf11/ littermates. b, insulin levels were also lower in Klf11/ animals than in Klf11/ littermates after overnight fasting. c, immuno-
histochemistry showsdecreased insulin immunoreactivitywithin Klf11/ islets, on the right as comparedwith Klf11/ littermates, on the left. Representative
images are shown, and semiquantitative evaluation is depicted as a bar graph on the right. Scale bar, 200 m. d, Ins2mRNA levels were significantly lower in
pancreata from Klf11/mice comparedwith Klf11/ littermate values bymicroarray (left panel) and RT-PCR (right panel). e, OGTT in Klf11/mice showpeak
glucose levels at 20min in both groups, although values in Klf11/micewere lower than in Klf11/ littermates (left panel). Lower values were also observed
at 60 and 120 min. Serial plasma insulin levels corresponding to each time point of OGTT (right panel) are also shown.
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for fueling future investigations in this important field of
medical genetics.
An important focus of further discussion is how our mouse
model experiments hold congruency with the biochemical and
genetic data reported here. Fortunately, this animal has pro-
vided the ultimate test for a role of KLF11 in insulin homeosta-
sis. Indeed, Klf11/ animals display lower levels of pancreatic
insulin than control littermates, as documented by several tech-
niques. However, because insulin levels are not abolished, it is
likely that the other transcription factors involved in insulin
biosynthesis can compensate for the loss of Klf11, although not
completely. Although these data support the overarching
hypothesis of this study,we recognize that themost appropriate
model would be mutation of the c.-331 KLF site to recapitulate
the abnormal promoter using elegant, yet complex, kick-in
technology. Therefore, future studies involving the generation
of thesemice will be evenmore informative on themechanisms
underlying the c.-331CG mutation in NDM. Nevertheless,
the important data provided by our mouse model support that
KLF disruption results in impaired insulin homeostasis, which
is congruent with the main observations reported for KLF11 in
MODY and NDM in humans.
In summary, we have identified the c.-331CACCCbox in the
INS promoter as a novel, bona fide KLF binding site. We pro-
vide evidence that supports the role for KLF11 in the regulation
of this site and predict that impairment in its transcriptional
function leads to a disruption in insulin biosynthesis. The
importance of KLF11 in the regulation of insulin biosynthesis is
further illustrated by our mouse model experiments. Addition-
ally, we identify a small subset of KLF proteins that may also
regulate insulin biosynthesis that serve as the catalyst for defin-
ing the ultimate role of KLF proteins in diabetes. Collectively,
these results expand the known repertoire of key biochemical
functions controlled by KLF proteins and provide a well char-
acterized example of their critical participation in human
disease.
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